The European Medicines Agency is this week due to decide whether to back the approval of extended indications for a raft medicines that are already authorized in the EU. These include GW Pharmaceuticals’ Epidyolex, AstraZeneca’s Imfinzi and Eli Lilly’s Olumiant.
Requests by companies to broaden the therapeutic indication of around 20 products are listed as being up for an opinion...